Enhertu delivered a phase 3 trial win in early-stage breast cancer. Takeda spotlighted three late-stage readouts as a ...

In a statement sent to Fierce Pharma Marketing, Cristian Azcarate, argenx’s VP of patient strategy, said the company’s work ...

In the wake of mass restructuring efforts across the Department of Health and Human Services (HHS), the FDA has missed yet another approval decision target date. | GSK had expected to secure an FDA ...

During his first term, attempts by President Donald Trump to slash drug price | After failing in his first term to install a ...

The FDA’s Oncologic Drugs Advisory Committee (ODAC) is planning to host its first meeting under new agency commissioner Marty ...

Takeda was scrambling to accommodate for rapidly sinking profits from the hasty decline of ADHD mainstay Vyvanse with a 140 ...

Amneal Pharmaceuticals inked a collaboration deal with syringe maker Apiject that will see the New Jersey-based biopharma ...

With Teva entering the next stage of its sweeping restructuring plan, thousands of employees are slated to be let go from the ...